TetanustetanusNCT07724379
A Study of Tetanus Antibody of Healthy Adults
An observational study of Tetanus, run by Peking University First Hospital at 1 site in China.
Trial summary
The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is: 1. Analysis of tetanus antibody distribution across different age groups 2. Evaluation of the TQS method for determining antibody status 3. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Tetanus
- How many people
- 2,009 participants
- Where
- 1 siteChina
- Study dates
- 4 May 2025to 15 May 2026
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study will enroll healthy adults aged 18 years who reside in Beijing. Participants will be recruited voluntarily from the general population. Both males and females are eligible. Participants must be willing to provide a blood sample and complete a brief questionnaire regarding their vaccination history. Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded.
Who may be able to join
- Voluntarily sign the informed consent form；
- Be aged 18 years or older；
- Be willing to provide a blood sample for biochemical testing
Who cannot join
- Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
- Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
- Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University First Hospital
Beijing, Beijing Municipality, 100034
About this study
Official title: A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing
The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:
- Analysis of tetanus antibody distribution across different age groups
- Evaluation of the TQS method for determining antibody status
- Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.
- Conditions
- Tetanus
- Keywords
- Healthy Adults, Vaccination, Protective Efficacy, Observational Study, TQS, tetanus
- Medical subject headings
- Tetanus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| age group | 20-29;30-39;40-49;50-59;≥60 | |
| gender group | male; female | |
| education background | high school; bachelor; master; et al | |
| primary vaccination | ≥3 doses TTCV; < 3 doses TTCV; unknown | |
| last TTCV dose duration | ≤5 year;5-10 year; >10 year; unkown |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tetanus Antibody Level
Single blood draw
Measured: Baseline (single blood draw at enrollment)
Secondary outcomes (1)
tetanus antibody level by TQS/mTQS method
at baseline
Measured: Baseline (single blood draw at enrollment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study start4 May 2025
- Primary completion3 Mar 2026
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TetanusStudies of the same condition, open and under way.
- More trials run by Peking University First HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 2,009 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liu Si, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07724379
- Sponsor's protocol ID
- 2024R524
- Other IDs
- 2024IR10
- Acronym
- tetanus
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 24 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing
- ClinicalTrials.gov ID
- NCT07724379
- Acronym / sponsor ID
- tetanus / 2024R524
- Conditions
- Tetanus
- Keywords
- Healthy Adults, Vaccination, Protective Efficacy, Observational Study, TQS, tetanus
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,009 participants (actual)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 4 May 2025 (actual)
- Primary completion
- 3 Mar 2026 (actual)
- Study completion
- 15 May 2026 (actual)
- First posted
- 24 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:
- Analysis of tetanus antibody distribution across different age groups
- Evaluation of the TQS method for determining antibody status
- Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| age group | – | –20-29;30-39;40-49;50-59;≥60 |
| gender group | – | –male; female |
| education background | – | –high school; bachelor; master; et al |
| primary vaccination | – | –≥3 doses TTCV; < 3 doses TTCV; unknown |
| last TTCV dose duration | – | –≤5 year;5-10 year; >10 year; unkown |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study will enroll healthy adults aged 18 years who reside in Beijing. Participants will be recruited voluntarily from the general population. Both males and females are eligible. Participants must be willing to provide a blood sample and complete a brief questionnaire regarding their vaccination history. Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded.
Key inclusion criteria (3 listed)
- Voluntarily sign the informed consent form；
- Be aged 18 years or older；
- Be willing to provide a blood sample for biochemical testing
Key exclusion criteria (3 listed)
- Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
- Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
- Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Tetanus Antibody Level
Time frame: Baseline (single blood draw at enrollment)
Single blood draw
1 secondary outcome
tetanus antibody level by TQS/mTQS method
Time frame: Baseline (single blood draw at enrollment)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Tetanus
RecruitingPhase 1
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer
RecruitingPhase 2
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Pertussis (Whooping Cough), Diphtheria
RecruitingPhase 1/2
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
Diphtheria, Pertussis
RecruitingPhase 4
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Not yet recruitingPhase 1/2
Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)
Diptheria Immunization, Tetanus Immunization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tetanus, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tetanus Antibody Level (time frame: Baseline (single blood draw at enrollment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2026.